Lanean...
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
OBJECTIVES: To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions. METHODS: This open-label extension study recr...
Gorde:
Argitaratua izan da: | Ann Rheum Dis |
---|---|
Egile Nagusiak: | , , , , , , , , , , , , , , |
Formatua: | Artigo |
Hizkuntza: | Inglês |
Argitaratua: |
BMJ Publishing Group
2017
|
Gaiak: | |
Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5284338/ https://ncbi.nlm.nih.gov/pubmed/27130908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2015-208786 |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|